MarginsXMarginsX
Home › Markets › Health Care › EXOZ

eXoZymes Inc. (EXOZ)

EXOZ trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.99
+4.18% on the day
Market cap
$37.1M
Nano cap
Revenue · 2023
$70K
No prior year to compare
Net income · 2023
-$2.0M
-2909.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2023-12-31, https://www.sec.gov/Archives/edgar/data/2010788/000164117225001744/0001641172-25-001744-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2023-12-31.

Profile

FieldValue
TickerEXOZ on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2024
SEC CIK0002010788
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inNV

Financials · 2023

LineValue
Revenue$70K
Net income-$2.0M
Operating income-$1.8M
Net margin-2909.1%
Operating margin-2563.5%
Revenue growthNo prior-year revenue to compare
Cash$67K
Total assets$3.6M
P/E (computed)Net income was not positive
P/S (computed)529.8×

Warning signs

Cash runway
9.7 months
$5.7M cash at June 30, 2026
Share count, 1 year
+12.6%
2025-11-13 to 2026-11-13
Going-concern doubt
Yes
10-Q filed November 13, 2026
Insider net buying, 12 months
-$9K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Management has concluded that the Company's existing working capital is not sufficient to fund operations for twelve months from the date these condensed unaudited consolidated financial statements are issued and that substantial doubt exists about its ability to continue as a going concern due to anticipated funding shortfalls and the Company's pre-revenue status."
10-Q 2026-11-13
Cash and burn$5.7M cash; operating cash flow -$1.7M a quarter.Report 2026-06-30
Shares outstanding9,439,915 (2026-11-13); 8,387,250 a year earlier.Cover page 2026-11-13
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 5 424B5 takedowns, 5 at the marketLatest 2026-06-30
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorRBSM LLP, LAS VEGAS, Nevada, United StatesPCAOB Form AP 2026-03-31
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $6K, sold $15K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$2.9M-$1.6M$5.7MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q1 2026
2026-03-31
Not filed-$2.4M-$1.5M$1.4MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q4 2025
2025-12-31
Not filed-$2.7M-$2.0M$3.0MNo debt tagsNeeds four quarters10-K 2026-03-30
Q3 2025
2025-09-30
Not filed-$2.3M-$1.9M$5.1MNo debt tagsNeeds four quarters10-Q 2025-11-13
Q2 2025
2025-06-30
Not filed-$2.4M-$1.5M$7.0MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q1 2025
2025-03-31
Not filed-$1.9M-$1.1M$8.5MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q4 2024
2024-12-31
Not filed-$1.8M-$5.7M$9.7MNo debt tagsNeeds four quarters10-K 2026-03-30
Q3 2024
2024-09-30
Not filed-$1.7M-$542K$234KNo debt tagsNeeds four quarters10-Q 2025-11-13

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-12026-11-06
Latest annual report10-K2026-03-30
Latest quarterly / interim10-Q2026-11-13
Latest current report8-K2026-10-09
Latest proxyDEFA14A2026-09-28

Source: SEC EDGAR submissions feed, 131 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-13.0%
1 month-16.6%
3 months-36.2%
Year to date-64.9%
1 year-76.6%
From 52-week high-76.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
ELUTElutia Inc.$0.8229+0.35%$36.5M
CRBUCaribou Biosciences Inc.$0.3528-2.51%$38.1M
TILInstil Bio Inc.$5.75-5.43%$39.0M
KLRSKalaris Therapeutics Inc.$1.46-7.30%$34.8M
IMAImageneBio Inc.$3.20-7.78%$39.9M
LONALeonaBio Inc.$3.23-6.92%$30.4M
INMBINmune Bio Inc.$0.9464-9.87%$29.3M
CVMCel-Sci Corporation$1.66+29.69%$29.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier